HI
ACAD icon

Harbour Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Harbour Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,110
Closed -$26.6K – 2996
2023
Q2 		$26.6K Hold
1,110
– – ﹤0.01% 1645
2023
Q1 		$20.9K Hold
1,110
– – ﹤0.01% 1725
2022
Q4 		$17.7K Hold
1,110
– – ﹤0.01% 1733
2022
Q3 		$16K Hold
1,110
– – ﹤0.01% 1737
2022
Q2 		$16K Buy
+1,110
New +$20.7K ﹤0.01% 1737
2021
Q4 		$38K Sell
1,610
-200
-11% -$4.02K ﹤0.01% 1375
2021
Q3 		$30K Sell
1,810
-315
-15% -$6.07K ﹤0.01% 2062
2021
Q2 		$52K Buy
2,125
+2,025
+2,025% +$45.7K ﹤0.01% 1791
2021
Q1 		$3K Buy
+100
New +$4.4K ﹤0.01% 3050

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Harbour Investments's ACAD Position: Q3 2023 in Review

Harbour Investments sold out of Acadia Pharmaceuticals (ACAD) in Q3 2023, closing a stake of 1,110 shares — an estimated $26.6K sold.

Harbour Investments first reported a position in ACAD in Q1 2021 and held it in 9 quarters. The position peaked at $52K in Q2 2021. 248 funds tracked by Wall St. Rank hold ACAD as of Q3 2023.

  • Harbour Investments reported no remaining Acadia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Harbour Investments sold 1,110 Acadia Pharmaceuticals shares in Q3 2023, an estimated $26.6K.
  • Harbour Investments first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 9 quarters.
  • Harbour Investments's Acadia Pharmaceuticals position peaked at $52K in Q2 2021.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2023.

Based on Harbour Investments's 13F filing for Q3 2023, filed 15 Nov 2023.